Quantcast
Last updated on April 24, 2014 at 1:21 EDT

PARI Respiratory Launches PEP S

October 1, 2009

MIDLOTHIAN, Va., Oct. 1 /PRNewswire/ — Today, PARI Respiratory Equipment introduced the PEP S, a device that provides positive expiratory pressure that can be used with all PARI LC reusable nebulizers. PARI’s PEP S can be used alone or in combination with nebulizer therapies for airway clearance and lung strengthening exercises by cystic fibrosis patients.

“I believe the new PARI PEP S is an incredible new device that improves patient care in two very important areas. It reduces treatment time by combining the PEP procedure with needed nebulized treatments. It may also enhance medication deposition with effective airway clearance during the nebulized treatment, especially in patients that find other modes of airway clearance cumbersome,” said Dr. Sterling Simpson, pediatric pulmonologist, East Tennessee Children’s Hospital.

“PARI is continually striving to improve respiratory therapies, and the PEP S is a time saver for cystic fibrosis patients. The PEP S allows for combination therapy with all of our LC reusable nebulizers, including the LC Sprint,” said Geoff A. Hunziker, president of PARI Respiratory Equipment.

PARI’s PEP S has eight adjustable resistance settings, covering a large expiratory flow range while achieving optimal resistance rates. Patients suffering from cystic fibrosis, lung diseases with secretory problems, and atelectasis (collapse of part or all of a lung) use PEP therapy to improve lung function by loosening thick, sticky mucus. PEP therapy has been shown to increase response to inhaled bronchodilators and is recommended by both the Cystic Fibrosis Foundation and the American Association for Respiratory Care.

About Cystic Fibrosis (CF)

Today, more than 30,000 people in the United States have CF. CF is a chronic, debilitating genetic disease. A major characteristic of CF is production of abnormally thick, sticky mucus in the lungs, trapping bacteria and predisposing patients to lung infections, which continually damage their lungs.

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI’s worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Maker of the world’s leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. Its Vortex Holding Chamber’s anti-static, valved holding chamber improves the aerosol deposition of metered dose inhalers (MDIs). PARI’s North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at www.Pari.com

SOURCE PARI Respiratory Equipment, Inc.


Source: newswire